Combined oral and topical mesalazine treatment for extensive ulcerative colitis.
A 32-year-old white Jewish woman was referred to our clinic in October 2002 for a second opinion on the management of her active extensive ulcerative colitis that did not respond to oral mesalazine (mesalamine) 3.6 g/day. The severity of symptoms had affected her plans to have children. Laboratory investigations, including perinuclear antineutrophil cytoplasmic antibodies and antibodies to Saccharomyces cerevisiae, stool cultures, and sigmoidoscopy to 40 cm from the rectum, with biopsies. Moderate-to-severe active extensive ulcerative colitis, unresponsive to mesalazine at 3.6 g/day. Oral mesalazine 4.8 g/day and 4 g mesalazine enemas nightly.